Keyphrases
Neoadjuvant Endocrine Therapy
100%
Pandemic Potential
100%
Treatment Paradigms
66%
COVID-19 Pandemic
66%
Breast Cancer
66%
Hormone Receptor-positive Breast Cancer
60%
Tumor Size
40%
Estrogen Receptor Status
40%
Hormone Receptor-positive
40%
Patient Delay
40%
Nodal Status
40%
Chemotherapy
26%
Prognostic Factors
26%
Alternative Treatment Strategies
20%
Radiologic
20%
Prognostic Impact
20%
Ki-67
20%
Prognostic Score
20%
Within-subject Design
20%
Hormone Receptor-positive Disease
20%
Early Disease
20%
Gaps in Care
20%
Trial Population
20%
Presurgical Treatment
20%
Endocrine Drugs
20%
Radiological Response
20%
Surgical Care
20%
Early Tumor
20%
Ki-67 Expression
20%
Stage at Diagnosis
20%
Support System
20%
Stage II-III
20%
Cytoreduction
20%
Large Tumors
20%
Clinical Endpoints
20%
Strong Potential
13%
University of North Carolina
13%
Health Systems
13%
Operative
13%
Usual Care
13%
Breast Cancer Patients
13%
Cell Proliferation
13%
Cancer Morbidity
13%
Clinical Response
13%
Patient's Will
13%
Cancer Mortality
13%
Non-inferiority Trial
13%
Medicine and Dentistry
Hormone Therapy
100%
Breast Cancer
66%
Pandemic
66%
Hormone Receptor
50%
Neoplasm
25%
Prognostic Factor
16%
Surgery
16%
Estrogen Receptor
16%
Disease
16%
Cancer Staging
12%
Receptor Expression
8%
COVID-19
8%
Cancer Mortality
8%
Clinical Trial
8%
Health System
8%
Cell Proliferation
8%